Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020
Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020
SUMMARY
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Multiple Myeloma (Kahler Disease), Pulmonary Radiation Toxicity, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Respiratory Distress Syndrome, Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Leukemia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sarcomas, Solid Tumor, Traumatic Brain Injury and Triple-Negative Breast Cancer (TNBC).
The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Nicotinamide phosphoribosyltransferase (NAmPRTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity.
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System and Respiratory which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Multiple Myeloma (Kahler Disease), Pulmonary Radiation Toxicity, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Respiratory Distress Syndrome, Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Depression, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Leukemia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sarcomas, Solid Tumor, Traumatic Brain Injury and Triple-Negative Breast Cancer (TNBC).
The latest report Nicotinamide Phosphoribosyltransferase - Pipeline Review, H2 2020, outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)
- The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
AbbVie Inc
Aqualung Therapeutics Corp
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech USA Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Tianjin Hemay Pharmaceutical Co Ltd
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles
ALT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AU-4869 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enamptcumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemay-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-9274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-3154567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-82 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P7-C3A20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STF-118804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones
Featured News & Press Releases
Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury
Jun 02, 2020: Aqualung Therapeutics receives A $2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury
May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill
Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma
Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)
Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers
Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference
Aug 20, 2019: Aqualung Therapeutics receives $225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome
Aug 13, 2019: Aqualung Therapeutics submits patent application to USPTO
Aug 06, 2019: Aqualung Therapeutics filed patent for eNamptor
Jul 20, 2019: Aqualung Therapeutics provides update on eNamptor
Jul 13, 2019: Aqualung Therapeutics submits $3 million Department of Defense grant for eNamptor
Jun 05, 2019: Aqualung Therapeutics receives a $1.7 Million National Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury
Jun 04, 2019: Aqualung Therapeutics Corporation receives A $1.7 million National Institute of Health (NIH) fastrack award to develop an novel immune-based therapeutic antibody for critically Ill patients with acute lung injury
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Overview
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Companies Involved in Therapeutics Development
AbbVie Inc
Aqualung Therapeutics Corp
Aurigene Discovery Technologies Ltd
Calico LLC
Eli Lilly and Co
Genentech USA Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Tianjin Hemay Pharmaceutical Co Ltd
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Drug Profiles
ALT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AU-4869 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enamptcumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNE-617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemay-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-9274 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-3154567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OT-82 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P7-C3A20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NAMPT for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STF-118804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Dormant Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Discontinued Products
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) - Product Development Milestones
Featured News & Press Releases
Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury
Jun 02, 2020: Aqualung Therapeutics receives A $2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury
May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill
Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma
Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)
Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers
Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference
Aug 20, 2019: Aqualung Therapeutics receives $225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome
Aug 13, 2019: Aqualung Therapeutics submits patent application to USPTO
Aug 06, 2019: Aqualung Therapeutics filed patent for eNamptor
Jul 20, 2019: Aqualung Therapeutics provides update on eNamptor
Jul 13, 2019: Aqualung Therapeutics submits $3 million Department of Defense grant for eNamptor
Jun 05, 2019: Aqualung Therapeutics receives a $1.7 Million National Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury
Jun 04, 2019: Aqualung Therapeutics Corporation receives A $1.7 million National Institute of Health (NIH) fastrack award to develop an novel immune-based therapeutic antibody for critically Ill patients with acute lung injury
Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AbbVie Inc, H2 2020
Pipeline by Aqualung Therapeutics Corp, H2 2020
Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
Pipeline by Calico LLC, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Genentech USA Inc, H2 2020
Pipeline by Karyopharm Therapeutics Inc, H2 2020
Pipeline by OncoTartis Inc, H2 2020
Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by AbbVie Inc, H2 2020
Pipeline by Aqualung Therapeutics Corp, H2 2020
Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
Pipeline by Calico LLC, H2 2020
Pipeline by Eli Lilly and Co, H2 2020
Pipeline by Genentech USA Inc, H2 2020
Pipeline by Karyopharm Therapeutics Inc, H2 2020
Pipeline by OncoTartis Inc, H2 2020
Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
